<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=3993628&amp;fmt=gif">

PLP-induced EAE Model

A preclinical model for evaluating efficacy in relapsing remitting multiple sclerosis.


Speak with a scientist

Remitting relapsing PLP-induced EAE Efficacy Model for MS Research


Proteolipid Protein (PLP) is a major protein component of CNS myelin. Sections of PLP, such as peptide fragment 139-151, are encephalitogenic to certain mouse strains. PLP injected in Swiss Jim Lambert (SJL) mice together with pertussis toxin (PT) will lead to remitting and relapsing demyelinating disease. Relapses are associated with epitope spreading, in which T cells react to secondary endogenous peptides that emerge as a consequence of the initial phase of myelin destruction. Remissions are associated with a temporary loss of inflammatory cells from the CNS.


MD Biosciences incorporates a range of in vivo measures and endpoint assessments that provide a robust data package that enable researchers to make critical decisions. 

Pain behavioral anaysis


Pain behavior tests include dynamic weightbearing and Hargreaves to assess the distribution on each paw and sensitivity to heat.  



Evaluate pro-inflammatory and anti-inflammatory biomarkers from CSF samples. 



IHC and histological staining to evaluate inflammatory markers in the paw skin. 

Scientific Data

Clinical score in the PLP-induced EAE model indicating the peaks of disease. The first phase of the disease begins around day 10 and subsides around day 25. On day 40 the relapse begins. 

PLP clinical score data
Review the complete dataset.

EAE datasheet


Download datasheet


If you are ready to discuss how a partnership can fit into your development program, our scientists are eager to explore the possibilities with you. Like many other pharmaceutical and medical device developers, you can rely on predictive preclinical data.

Request Proposal